RETINA-AI Health, Inc.

RETINA-AI Health, Inc. is a US-based company focused on enhancing diabetic retinopathy screening through advanced artificial intelligence technology, providing rapid diagnoses to support healthcare providers and improve patient outcomes. Founded in 2017 and headquartered in Houston, US, RETINA-AI Health, Inc. specializes in AI-driven solutions for diabetic retinopathy detection.

The company has raised a total of USD 5. 2 mn in funding, with the latest Series A round occurring on August 6, 2020. Stephen Odaibo serves as both the CEO and Founder of the firm. RETINA-AI specializes in the development of advanced artificial intelligence technology aimed at improving diabetic retinopathy screening in primary care settings.

Their flagship product, the RETINA-AI Galaxy, utilizes deep learning algorithms to automatically detect moderate or worse diabetic retinopathy (mowDRet) by analyzing retinal images captured by robotic cameras. The system provides diagnoses in under 10 seconds, enabling healthcare providers to refer patients to eye care professionals when necessary or recommend retesting in 12 months if no disease is detected. The Galaxy system is compatible with multiple robotic camera models, including Centervue DRSPlus, Crystalvue NFC-700, and Topcon NW400, allowing for broader deployment across various healthcare facilities. RETINA-AI's solutions cater primarily to primary care physicians, insurers, and patients in North America, aiming to enhance early detection and treatment of diabetic retinopathy to prevent vision loss.

RETINA-AI operates a revenue model that includes partnerships with healthcare providers and insurers, leveraging reimbursement opportunities through established CPT codes such as 92229. The firm generates revenue by offering their diagnostic services on a per-exam basis, ensuring immediate and actionable results are delivered during patient visits. This structure facilitates smooth transactions with primary care practices, where medical assistants conduct the retinal imaging, and results are provided in real-time. By integrating their technology into existing healthcare workflows, RETINA-AI enhances service offerings for providers and creates additional revenue streams through improved patient care and compliance with healthcare metrics.

Following the Series A funding round in August 2020, RETINA-AI Health, Inc. aims to leverage the USD 5. 2 mn raised to further develop its technology and expand into additional healthcare markets. The company plans to enhance the capabilities of the RETINA-AI Galaxy and introduce new products aimed at improving diabetic retinopathy detection.

Specific geographic regions for expansion include further outreach in North America, targeting new partnerships with healthcare providers and insurers to broaden their service offerings. The company seeks to implement these initiatives over the next few years.